Search

The only known, effective intervention for non-alcoholic fatty liver disease (NAFLD) is weight loss, and there is no approved pharmacotherapy. Recently, new hypoglycemic agents, such as sodium-glucose cotransporter 2 (SGLT2) inhibitors and glucagon-like peptide-1 receptor agonists (GLP-1RAs), and their effects on NAFLD have received substantial interest. Herein, we review the currently available human studies regarding the effects of SGLT2 inhibitors and GLP-1RAs on NAFLD/non-alcoholic steatohepatitis in patients with type 2 diabetes mellitus, and we describe the possible mechanisms explaining the positive effects of these agents on NAFLD.

Background : Vitamin D deficiency is known to increase the incidence of metabolic syndrome. Nonalcoholic fatty liver disease is a common metabolic disease in patients with type 2 diabetes. This study evaluated nonalcoholic fatty liver disease and abdominal fat accumulation according to 25-hydroxyvitamin D status in patients with type 2 diabetes. Methods : The study comprised 302 patients with type 2 diabetes. Patients were divided into three groups based upon their 25-hydroxyvitamin D status: vitamin D deficient group (

Some clinical manifestations of obesity include nonalcoholic fatty liver disease, type 2 diabetes, and cardiovascular disease. Calorie restriction may aid in weight loss in the short term. Exercise and physical activity are other means of weight loss. However, the efficacy of exercise and physical activity in weight reduction in obese populations is still unknown. In this review, we discuss the effects of exercise and physical activity in obese and overweight populations. We also discuss the effects of aerobic exercise and/or resistance training in weight loss and maintenance.

Vitamin D affects not only musculoskeletal health but also a range of nonskeletal diseases such as cancer, obesity, metabolic syndrome, type 2 diabetes and cardiovascular disease. Vitamin D deficiency and obesity have been recognized as pandemic diseases with much health consequences. The ‘cause-effect’ relationship of vitamin D to obesity has been the area of much recent activity. There is consistent association in the published literature between higher body mass index (BMI) and lower 25-hydroxyvitamin D (25(OH)D) concentrations, but the mechanisms are not fully understood. Although recent studies suggest that low serum vitamin D is the consequence of obesity, the results from randomized controlled trials are still scarce and inconclusive to establish the relationship between vitamin D and obesity. Moreover, the role of vitamin D in the pathophysiology of obesity is still debatable and there is little evidence for a direct effect of vitamin D supplementation on body weight. Therefore, randomized large-scale double-blind controlled trials are needed in the future to clearly establish the effects of vitamin D in obesity.